178 related articles for article (PubMed ID: 27339366)
1. Minimal residual disease in canine lymphoma: An objective marker to assess tumour cell burden in remission.
Sato M; Yamazaki J; Goto-Koshino Y; Setoguchi A; Takahashi M; Baba K; Fujino Y; Ohno K; Tsujimoto H
Vet J; 2016 Sep; 215():38-42. PubMed ID: 27339366
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of minimal residual disease (MRD) in canine lymphoma by using real-time polymerase chain reaction.
Yamazaki J; Baba K; Goto-Koshino Y; Setoguchi-Mukai A; Fujino Y; Ohno K; Tsujimoto H
Vet Immunol Immunopathol; 2008 Dec; 126(3-4):321-31. PubMed ID: 18977540
[TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma.
Aresu L; Aricò A; Ferraresso S; Martini V; Comazzi S; Riondato F; Giantin M; Dacasto M; Guadagnin E; Frayssinet P; Rouquet N; Drigo M; Marconato L
Vet J; 2014 May; 200(2):318-24. PubMed ID: 24698669
[TBL] [Abstract][Full Text] [Related]
4. Increase in minimal residual disease in peripheral blood before clinical relapse in dogs with lymphoma that achieved complete remission after chemotherapy.
Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2011; 25(2):292-6. PubMed ID: 21314721
[TBL] [Abstract][Full Text] [Related]
5. Monitoring of minimal residual disease (MRD) after multidrug chemotherapy and its correlation to outcome in dogs with lymphoma: a proof-of-concept pilot study.
Yamazaki J; Takahashi M; Setoguchi A; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2010; 24(4):897-903. PubMed ID: 20492493
[TBL] [Abstract][Full Text] [Related]
6. Retrospective monitoring of minimal residual disease using hairpin-shaped clone specific primers in B-cell lymphoma affected dogs.
Gentilini F; Turba ME; Forni M
Vet Immunol Immunopathol; 2013 Jun; 153(3-4):279-88. PubMed ID: 23602204
[TBL] [Abstract][Full Text] [Related]
7. Detection of circulating tumor cells using GeneScan analysis for antigen receptor gene rearrangements in canine lymphoma patients.
Hiyoshi-Kanemoto S; Goto-Koshino Y; Fukushima K; Takahashi M; Kanemoto H; Uchida K; Fujino Y; Ohno K; Tsujimoto H
J Vet Med Sci; 2016 Jun; 78(5):877-81. PubMed ID: 26888583
[TBL] [Abstract][Full Text] [Related]
8. Minimal residual disease in lymph nodes after achievement of complete remission predicts time to relapse in dogs with large B-cell lymphoma.
Chalfon C; Martini V; Comazzi S; Aresu L; Stefanello D; Riondato F; Ferrari R; Marconato L
Vet Comp Oncol; 2019 Jun; 17(2):139-146. PubMed ID: 30578621
[TBL] [Abstract][Full Text] [Related]
9. MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCR.
Pott C; Brüggemann M; Ritgen M; van der Velden VH; van Dongen JJ; Kneba M
Methods Mol Biol; 2013; 971():175-200. PubMed ID: 23296964
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cytoreductive efficacy of vincristine, cyclophosphamide, and Doxorubicin in dogs with lymphoma by measuring the number of neoplastic lymphoid cells with real-time polymerase chain reaction.
Sato M; Yamazaki J; Goto-Koshino Y; Takahashi M; Fujino Y; Ohno K; Tsujimoto H
J Vet Intern Med; 2011; 25(2):285-91. PubMed ID: 21314729
[TBL] [Abstract][Full Text] [Related]
11. Monitoring minimal residual disease in canine lymphomas treated with modified L-COP or L-CHOP protocols.
Sirivisoot S; Teewasutrakul P; Techangamsuwan S; Tangkawattana S; Rungsipipat A
Acta Vet Hung; 2018 Mar; 66(1):66-84. PubMed ID: 29580085
[TBL] [Abstract][Full Text] [Related]
12. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects.
van der Velden VH; Hochhaus A; Cazzaniga G; Szczepanski T; Gabert J; van Dongen JJ
Leukemia; 2003 Jun; 17(6):1013-34. PubMed ID: 12764363
[TBL] [Abstract][Full Text] [Related]
13. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL.
Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A
Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018
[TBL] [Abstract][Full Text] [Related]
14. Common consensus LNA probe for quantitative PCR assays in cancer: vehicles for minimal residual disease detection in t(11;14) and t(14;18) positive malignant lymphomas.
Sørensen CD; Jørgensen JM; Nederby L; Hokland P; Nyvold CG
J Immunol Methods; 2014 Apr; 406():131-6. PubMed ID: 24631717
[TBL] [Abstract][Full Text] [Related]
15. Minimal Residual Disease Detection by Droplet Digital PCR in Multiple Myeloma, Mantle Cell Lymphoma, and Follicular Lymphoma: A Comparison with Real-Time PCR.
Drandi D; Kubiczkova-Besse L; Ferrero S; Dani N; Passera R; Mantoan B; Gambella M; Monitillo L; Saraci E; Ghione P; Genuardi E; Barbero D; Omedè P; Barberio D; Hajek R; Vitolo U; Palumbo A; Cortelazzo S; Boccadoro M; Inghirami G; Ladetto M
J Mol Diagn; 2015 Nov; 17(6):652-60. PubMed ID: 26319783
[TBL] [Abstract][Full Text] [Related]
16. Utility of a multiple serum biomarker test to monitor remission status and relapse in dogs with lymphoma undergoing treatment with chemotherapy.
Alexandrakis I; Tuli R; Ractliffe SC; Tappin SW; Foale RD; Roos A; Slater KJ
Vet Comp Oncol; 2017 Mar; 15(1):6-17. PubMed ID: 25319380
[TBL] [Abstract][Full Text] [Related]
17. Significance of minimal residual disease in lymphoid malignancies.
Brüggemann M; Pott C; Ritgen M; Kneba M
Acta Haematol; 2004; 112(1-2):111-9. PubMed ID: 15179011
[TBL] [Abstract][Full Text] [Related]
18. Clonality and phenotyping of canine lymphomas before chemotherapy and during remission using polymerase chain reaction (PCR) on lymph node cytologic smears and peripheral blood.
Thilakaratne DN; Mayer MN; MacDonald VS; Jackson ML; Trask BR; Kidney BA
Can Vet J; 2010 Jan; 51(1):79-84. PubMed ID: 20357946
[TBL] [Abstract][Full Text] [Related]
19. Bone marrow minimal disseminated disease (MDD) and minimal residual disease (MRD) in childhood T-cell lymphoblastic lymphoma stage III, detected by flow cytometry (FC) and real-time quantitative polymerase chain reaction (RQ-PCR).
Stark B; Avigad S; Luria D; Manor S; Reshef-Ronen T; Avrahami G; Yaniv I
Pediatr Blood Cancer; 2009 Jan; 52(1):20-5. PubMed ID: 19006253
[TBL] [Abstract][Full Text] [Related]
20. [Characteristics of T cell receptor beta gene rearrangements and its role in minimal residual disease detection in childhood T-cell acute lymphoblastic leukemia].
Liu JY; Li ZG; Gao C; Cui L; Wu MY
Zhonghua Er Ke Za Zhi; 2008 Jul; 46(7):487-92. PubMed ID: 19099802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
